Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
9.63
+0.12 (1.26%)
Jul 18, 2025, 3:08 PM - Market open

Jade Biosciences Stock Forecast

Stock Price Forecast

The 2 analysts that cover Jade Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $15.5, which forecasts a 60.96% increase in the stock price over the next year. The lowest target is $14 and the highest is $17.

Price Target: $15.5 (+60.96%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$14$15.5$17$17
Change+45.38%+60.96%+76.53%+76.53%
* Price targets were last updated on Jun 16, 2025.

Analyst Ratings

The average analyst rating for Jade Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMay '25Jun '25Jul '25
Strong Buy011
Buy111
Hold000
Sell000
Strong Sell000
Total122

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Strong Buy
Upgrades
$14
Strong BuyUpgrades$14+45.38%Jun 16, 2025
Wedbush
Wedbush
Buy
Reiterates
$17
BuyReiterates$17+76.53%May 15, 2025
Wedbush
Wedbush
Buy
Initiates
$17
BuyInitiates$17+76.53%May 7, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
10.39M
Revenue Next Year
n/a
from 10.39M
EPS This Year
-5.90
from -18.79
EPS Next Year
-25.58
from -5.90
Fiscal YearFY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
-10.39M-
Revenue Growth
----
EPS
-18.79-5.90-25.58-2.59
EPS Growth
----
Forward PE
----
No. Analysts
-775
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
Highn/a42.8Mn/a
Avgn/a10.4Mn/a
Lown/an/an/a

Revenue Growth

Revenue Growth202520262027
High---
Avg---
Low---

EPS Forecast

EPS202520262027
High-1.22-1.75-2.38
Avg-5.90-25.58-2.59
Low-18.52-114.56-2.84

EPS Growth

EPS Growth202520262027
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.